MA11.09 SAKK 16/18: Neoadjuvant Chemotherapy, Durvalumab and Immune-Modulatory RT in Stage III(N2) NSCLC. Surgical Interim Analysis

For patients (pts) with resectable stage III(N2) non-small cell lung cancer (NSCLC), the single-arm SAKK 16/14 trial suggested significant improvements in pathological complete response (pCR), major pathological remission (MPR), and event-free survival (EFS) with the addition of perioperative durvalumab to standard neoadjuvant chemotherapy (ChT) with cisplatin and docetaxel. The ongoing SAKK 16/18 trial is evaluating whether immune-modulatory radiotherapy (RT) administered concurrently with neoadjuvant durvalumab can further improve efficacy outcomes.